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ABSTRACT 
 
 Onchocerca volvulus is a filarial parasite transmitted to humans by female 
Simulium spp. black flies. Infection with this parasite can cause blindness and severe 
skin disease among humans in Africa and the Americas. Enzyme-linked Immunosorbent 
Assay serological testing of OV-16 antigen is a diagnostic tool for determining effective 
elimination of the parasite. Programs typically rely on OV–16 ELISA to evaluate the 
progress towards interruption and/or elimination of disease by mass drug distribution of 
ivermectin and vector larvicidal control efforts. As elimination grows closer, monoclonal 
antibody positive controls for OV-16 ELISA become important to develop for 
Onchocerca testing due to the limited availability of pooled sera positive controls. 
Recent evaluation of laboratory designed OV-16 ELISA coating antigen by the Unnasch 
Lab (University of South Florida) showed that polymorphisms occurred which may alter 
the ability of the humanized monoclonal antibody to recognize the cognate antigen. With 
this development, it was important to evaluate these polymorphisms and isolate them 
for further testing against the standardized monoclonal antibody and positive sera to 
determine the effects antigenic polymorphisms could have on diagnostic testing. Upon 
evaluation, the polymorphisms did influence signaling when testing the monoclonal 
antibody. However, little effect on the recognition of the antigen was seen when different 
isoforms were evaluated against sera from O. volvulus infected individuals. Data 
suggest that the epitope recognized by the synthetically produced monoclonal antibody 
is not immuno-dominant in infected individuals.
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CHAPTER ONE: 
 
INTRODUCTION 
 
 Onchocerciasis, sometimes referred to as “River Blindness”, is one of the 
neglected tropical diseases (NTDs) affecting humankind and has been documented as 
one of the most common causes of preventable infectious blindness (WHO, 2016). 
However, Onchocerciasis is also one of the NTDs which has the potential for elimination 
through vector control measures and the efforts of mass distribution of microfilaricidal 
treatments by multiple health response alliances with the support of the World Health 
Organization (WHO) (WHO, 2016). 
This debilitating disease is caused by a parasitic filarial nematode known as 
Onchocerca volvulus (Coffeng, et al., 2013). Although there are other Onchocerca spp. 
which have been identified to infect mammals, such as; O. ochengi in cattle, O. lupi in 
canines, and O. cervipedis in deer, O. volvulus appears to selectively target humans as 
its only host (Boatin & Amazigo, 2016). Onchocerciasis has the potential to manifest in 
either an ocular form of illness, lymphatic involvement, or display in the form of filarial 
dermatitis, and the severity of disease appears to be linked to repeated exposure to 
infective bites (Dobson, 2008).  
Human infection of O. volvulus occurs from the bite of a previously infected 
blackfly, which upon inoculation the L3 larvae will complete their cycle to reproductive 
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adulthood in approximately 24 months within the human host (Boatin & Amazigo, 2016; 
WHO, 2016). Adult female O. volvulus form nodules within the body, usually near bony 
prominences, where they have the ability to reside for upwards of 14 years and produce 
first stage larvae (microfilariae) at a reproductive potential of “700-1500 per day” (Liu, 
2013). The microfilariae that are produced leave these nodules and take up residence in 
the skin, and in some cases the eye, where they can survive for up to two years (Liu, 
2013). In this human infective stage, the microfilariae are taken up by the black fly 
vector during blood-feeding and perpetuate the cycle upon molting to L3 larvae within 
the black fly’s thoracic flight muscles and eventually exit the labium during subsequent 
feeding to further transmission (McClelland, 1992). 
It is estimated that 37 million individuals are infected with O. volvulus (Heymann, 
2008). The disease predominantly affects individuals in sub-Saharan Africa wherein 
approximately 99% of onchocerciasis cases in the world occur, with a few foci also 
noted in the Americas and Eastern Mediterranean (Noma et al., 2014; WHO, 2016). 
There does appear to be a geographical component to the distribution and 
symptomology of the disease. There are noted divisions in distribution of disease where 
“blinding” illnesses appear to be more prevalent in the savannah foci, “non-blinding” 
illnesses tend to occur in forest foci and this might be explained by varying vector-
parasite complexes with the different strains of O. volvulus (Boatin & Amazigo, 2016).  
The black fly (Simulium spp.) vector for onchocerciasis prefers a habitat of fast 
flowing water found in rivers and streams. Unfortunately for developing countries, this 
has created a cyclical paradigm between onchocerciasis and malnutrition, as 
communities attempt to avoid the risk of disease they also regress to inferior farmland 
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(Dobson, 2008). Unfortunately, the plight of this disease does not stop with the illnesses 
that it evokes, it also causes economic strain on the affected communities. However, 
great efforts have been made in targeting these black fly environments with control 
measures as noted in early achievements of the Onchocerciasis Control Programme in 
West Africa (OCP), which initially started targeting habitat control with larvicides in the 
1970’s and later added human microfilaricidal treatments to their arsenal using 
ivermectin in the late 1980’s (Dobson, 2008; Unnasch, 2004). Other programs such as; 
the African Program for Onchocerciasis (APOC) and Onchocerciasis Elimination 
Program in the Americas (OEPA) have mass treatment strategies in pursuit of 
interruption and eradication of O. volvulus (Eisenbarth et al., 2016). 
With control program measures in place and ongoing human treatment with 
mass drug administration (MDA) of “Mectizan ® from Merck & Co.”, onchocerciasis is 
making its way towards elimination (Schwab, 2007). In fact, recent research indicates 
that Colombia, Ecuador, Mexico, and Guatemala have reached elimination status, and 
several foci have thought to have interrupted the disease, including foci in Uganda and 
the Sudan (Boatin & Amazigo, 2016; Higazi et al., 2013; WHO, 2016). As research 
continues to evaluate the progress of the MDA program and vector control measures it 
appears that onchocerciasis elimination is possible within endemic regions still affected 
by disease. That being said, as interruption and elimination approaches, challenges will 
inevitably continue to arise in determining the future risk of reemergence in previously 
endemic regions. 
The gold standard of diagnosis for O. volvulus has historically been through the 
microscopic evaluation of skin biopsies (skin snips) for the appearance of microfilariae 
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after clinical pathology of disease has been determined via ocular damage, palpable 
nodules, or perhaps by dermatological symptoms (Liu, 2013). Generally, these skin 
snips are obtained using a sclerocorneal biopsy punch that excises approximately 
2.5mm of tissue, that is then incubated in culture media or saline wherein the 
microfilariae exit the tissue and the fluid can be examined for their presence (Boatin & 
Amazigo, 2016; Liu, 2013). Unfortunately, this diagnostic method can be painful and 
could potentially result in underestimation of disease burden due to limitations in the 
number of accommodating participants.  
The paradox of MDA treatment programs is that it may lead to fewer detectable 
microfilariae in each patient and could allow for underestimation of disease in foci that 
are near or at elimination status. Assays like the Ov-16 enzyme-linked immunosorbent 
assay (ELISA) are used to geographically map the distribution of onchocerciasis and 
monitor control program progress, but many such filariasis assay applications have 
been noted to have issues regarding cross reactivity and deficiencies with 
standardization (Weil, et al., 2011). Currently, the Ov-16 ELISA is used to evaluate 
successful suppression of the disease by investigating potential exposure to the 
parasite in children less than 10 years old (Cupp, et al., 2012). Exposure is determined 
by the ELISA detecting IgG4 antibodies against Ov16, a 16kDa immunodominant 
antigen. Children are tested as sentinels for continued or emerging exposure, as Ov-16 
ELISA is limited to evaluating antibodies that are exhibited post exposure which may 
also be present in individuals who were previously infected and treated.  
As elimination approaches in a given region, the limited availability of positive 
sera for use as controls in diagnostic tests like Ov-16 ELISA adds to the complex 
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challenges of having sufficient diagnostic tools available for monitoring the progress 
towards onchocerciasis elimination (Golden et al., 2016). Recently, a humanized 
monoclonal antibody was produced as a positive control for use in Ov-16 ELISA to help 
solve this dilemma (Golden et al., 2016). As low levels of parasitemia become more 
common due to the current MDA programs, the monoclonal antibody design seems an 
advantageous alternative to the previous techniques of pooled sera. Designing 
standardized positive controls also reflects the need to have universal applications and 
reproducibility of these required conjugates in the current onchocerciasis surveillance 
programs in order to evaluate various foci and potential elimination and/or transmission 
status properly.   
Upon evaluating the efficacy of the humanized monoclonal antibody against Ov-
16 ELISA within the Unnasch laboratory (University of South Florida), difficulties arose 
in the ability of the Ov-16 antigen to appropriately detect the humanized monoclonal 
antibody. It was determined that this monoclonal antibody, produced as a positive 
control for the Ov-16 ELISA, reacted to a recombinant version of the Ov-16 antigen 
derived from parasites from Guatemala and was unable to bind to a homologue derived 
from a sequence obtained from parasites from Cameroon. It is not uncommon to exploit 
the antigen antibody interactions in designing surveillance test formats when diagnosing 
filarial infections, but there are known drawbacks including cross reactivity with 
nematode infections other than the target, in this case O. volvulus (Lammie, 2004). 
Therefore, designing a humanized monoclonal antibody that recognizes the 
immunodominant antigen appropriately with specificity for an Onchocerca testing 
platform is important. 
6 
 
Through investigation, the Unnasch laboratory discovered that polymorphisms 
occurring in the Ov-16 coating antigen may further explain the effect on the ability of the 
monoclonal antibody to recognize the antigen via Ov-16 ELISA assay. Upon genetic 
analysis by the Unnasch laboratory, it was discovered that two distinct polymorphisms 
had occurred at amino acids 167 & 196 in the Ov-16 antigens derived from Guatemala 
and Cameroon. The polymorphisms found differing in the Cameroon antigen had 
altered at amino-acid 167 arginine to proline (167R>P) and 196 arginine to proline 
(196R>P) (Fig. 1).  
 
 
Figure 1: Amino acid sequence of O. volvulus parasites showing polymorphisms 
 
 
Having determined these polymorphisms were present, it was important to 
evaluate them in the Ov-16 coating antigen and isolate them for further testing. Clones 
were produced by in-vitro mutagenesis for each of the antigens to be tested; one clone 
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containing no mutations reflecting the Guatemalan strain (parental construct), one clone 
containing a single mutation at 167R-P (arginine to proline), one clone containing a 
single mutation at 196R-P (arginine to proline), and one clone containing both 
mutations. Each of the mutated Ov-16 antigens was expressed with a GST tag and 
purified using affinity chromatography. Once purified, these four laboratory designed 
Ov-16 antigens (OV-16:167R196R, OV-16:167P196P, OV-16:167P196R, & OV-
16:167R196P) could then be tested against the monoclonal antibody, as well as a set of 
known positive sera via Ov-16 ELISA in order to identify the polymorphism responsible 
for the loss in monoclonal activity and to determine if the polymorphisms affected the 
sensitivity of the Ov-16 ELISA.        
The aim of this research was designed to investigate the performance of Ov-16 
ELISA with respect to four variant recombinant Ov-16 antigens to evaluate the noted 
polymorphisms. Objective comparisons of these Ov-16 antigens containing isolated 
polymorphisms to an Ov-16 antigen that contained no polymorphisms were performed 
to determine whether or not these isoforms infer functional similarity on serological 
testing within the Ov-16 ELISA platform. Investigation regarding reactivity to the 
humanized monoclonal antibody was also performed to determine the effects antigenic 
polymorphisms may have on such synthetic positive controls. With onchocerciasis 
interruption and elimination in sight and fewer infections occurring, future test 
applications may soon rely on the development of adequate humanized monoclonal 
antibody standardization techniques. However, these synthetic positive controls should 
be designed to react appropriately with an immunodominant antigen that is specific to 
O. volvulus and sensitive to detection when present in sera if it is to replace the need for 
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pooled sera positive controls in current onchocerciasis surveillance programs (Lucius, 
1988). Furthermore, the World Health Organization’s certification of elimination protocol 
relies heavily on the Ov-16 ELISA testing platform in their Onchocerciasis surveillance 
programs which warrants quality control efforts to ensure that these serological assays 
perform to the highest standards possible, as the results of such testing will ultimately 
dictate how screening children in each focus will proceed (Cupp, et al., 2012).  
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CHAPTER TWO: 
 
MATERIALS AND METHODS 
 
Isolation and Purification of Mutations for Use in OV-16 ELISA 
 Four clones were produced, one for each of the laboratory Ov-16 antigens, by in-
vitro mutagenesis and plasmids (pGEX, a commonly used expression vector) were 
maintained at -80o C, by Dr. Canhui Liu in the Unnasch laboratory. 1ul of each of the 
plasmid was inoculated into 25ul BL-21 competent E-coli cells and incubated on ice for 
5 minutes then heat shocked at 42o C 45 seconds. They were immediately placed on ice 
for two minutes after which time 900ul of SOC buffer was added and tubes were 
incubated in platform shaker at 37o C for one hour. After incubation, a 1:10 dilution of 
positive cells was created and 125ul of cells were plated on LB Agar plates containing 
Ampicillin at a concentration of 100ug/ml, along with negative control plates, and 
incubated upside down at 37o C overnight. Positive plates were examined the next day 
for presence of colonies, as well as no colonies confirmed in negative control plates. 
Individual E. coli colonies containing the transformed plasmids were chosen from each 
of the Ov-16 plasmid clones and grown using LB media containing Ampicillin100ug/ml 
in step-wise proportions starting with 5ml of media incubated overnight at 37o C and 
shaking at 300 RPM. The 5ml overnight culture was then diluted to 100ml with LB 
media containing Ampicillin 100ug/ml and incubated overnight under the same 
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conditions. 50ml of this overnight culture was then added to 1 liter of LB media 
containing Ampicillin 100ug/ml, incubated at 37o C and 300 RPM to mid-log phase by 
monitoring optical densities at A600 to a value between 0.6 - 1.0. Once these values 
were reached, protein expression was induced by adding isopropyl-β D-thiogalactoside 
(IPTG) to a final concentration of 0.1mM. An additional OD reading was taken 1 hour 
following the addition of IPTG to confirm growth was continuing and the cells were 
allowed to grow overnight at 37o C and 300 RPM. After growth was complete, the media 
containing each protein/Ov-16 antigen was then divided into 250ml cell centrifuge tubes 
and the cell pellet concentrated via centrifugation at 13,000 RPM for 10 minutes at 4o C. 
Cells are resuspended in cold GST binding buffer (150mM NaCl, 25mMTris, 1mM 
EDTA) containing protease inhibitors (Thermo ® Protease Inhibitor tablets Cat.#78430) 
and 100ug/ml lysozyme. This was then followed by the addition of Triton x100 detergent 
to a final concentration of 0.5% to assist in lysing cells after which the cell pellets were 
placed at -80o C overnight. 
 Each of the isolated Ov-16 antigens was individually purified by affinity 
chromatography using GSTrap HP® columns (GE Healthcare Life Sciences). This 
process began by thawing the cell pellets and sonicating them at 15% for 10 seconds 
with a one minute pause on ice, over three intervals to lower the viscosity. The cell 
debris was then centrifuged at 18,000rpm for 30 minutes at 4o C. and the supernatant 
was retained and filtered through a 0.45um filter prior to its application to the affinity 
column. Using a separate 1.0ml GSTrap® column for each of the four Ov-16 antigens, 
all were purified under the same conditions using an infusion pump at a wash flow-rate 
of 1.0ml/min., a sample loading flow-rate of 0.2ml/min., and an elution flow-rate of 
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1.0ml/min. wherein all samples and buffers were maintained on ice. Important to note 
that the slower flow-rate for sample loading is recommended for increased binding of 
desired protein. The following buffers were used in all four purifications; binding buffer – 
10mM sodium phosphate,140mM NaCl, 2.7mM KCl at pH of 7.4 and elution buffer – 
50mM Tris/HCl, 10mM reduced glutathione at a pH of 8.0. The elutions retrieved from 
the four purifications were evaluated via the Nano-drop® and SDS gel electrophoresis 
to confirm presence of desired Ov-16 protein prior to following up with dialysis on each 
of them. Dialysis was performed on each protein using 3.0ml Thermo Scientific Slide-A-
Lyzer ® dialysis cassettes immersed in 1X PBS. SDS gel electrophoresis was then 
repeated on the four Ov-16 antigens post dialysis.  Each of the Ov-16 antigens was 
given a label designation based on their mutation characteristics and yield 
concentrations were calculated via Bradford ® Protein assay (Table 1). 
 
 
             Table 1: List of purified OV-16 proteins with yield concentrations in mg/ml 
 
Monoclonal Standards via OV-16 ELISA Against 4 Experimental Antigens 
 In previous research performed by Golden et al. (2016), a humanized 
monoclonal antibody was designed for positive controls in the OV-16 ELISA. Using a 
Purified OV-16 protein ID Yield Concentration 
in mg/ml 
Polymorphism Characteristics 
OV-16:167R196R 2.0 mg/ml Parental construct 
OV-16:167P196P 2.0 mg/ml Double mutation; 167R>P & 196R>P 
OV-16:167P196R 0.5 mg/ml Isolated single mutation; 167R>P 
OV-16:167P196R 1.0 mg/ml Isolated single mutation; 196R>P 
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human combinatorial antibody library (HuCAL & HuCAL Platinum), they were able to 
identify 15 unique antibody clones with specificity for Ov-16, which were then narrowed 
down to two based on binding affinity in ELISA and nitrocellulose platforms (Golden et 
al.,2016). Ultimately one recombinant antibody clone was chosen for development 
(AbD19432_hIgG4) based on absorbance range and signal strength (Golden et 
al.,2016). As previously noted upon testing in the Unnasch Laboratory, it was found that 
this humanized monoclonal antibody produced as a positive control for the Ov16 ELISA 
reacted to a recombinant version of the Ov16 antigen derived from parasites from 
Guatemala but did not react to a homologue derived from a sequence obtained from 
parasites from Cameroon. After careful isolation of the polymorphisms, the experimental 
Ov-16 mutations were tested individually against the humanized monoclonal antibody 
(AbD19432_hIgG4). The monoclonal antibody was serially diluted and tested via OV-16 
ELISA techniques using the four experimental OV-16 antigens to evaluate detection. 
Optical densities were evaluated via spectroscopy at 405nm as per OV-16 ELISA 
protocols and results of each of the four antigens were compared.  
 
Testing Ov-16 Polymorphisms in Sera via ELISA 
To determine the effects that Ov-16 antigenic polymorphisms may have on 
serum reactivity regarding naturally acquired human antibodies in endemic regions, the 
four recombinant Ov-16 antigens were evaluated via OV-16 ELISA against 704 
specimens that were collected from Liberia and Ghana. These serum samples 
contained no personal identifiers and the University of South Florida’s IRB ruled on 
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9/16/16 that this work did not meet the definition of human subjects research. Standard 
Ov-16 ELISA protocols were used to evaluate the sensitivity of the four experimental 
Ov-16 antigens against the 704 serum samples. All 704 samples were previously 
determined positives for O. volvulus via skin snip results. For effective comparison of 
serum reactivity, each of the ELISA 96-well microtiter plates were divided such to be 
coated with all four experimental Ov-16 antigens (100ul per well) at 2.0ug/ml in 
carbonate buffer (NaHCO3) (Fig. 2).  
 
 
 
 
Figure 2: OV-16 ELISA; Plate Map of 4 recombinant antigens     
 
Coating Antigens 
OV-16:167R196R       (NO MUTATIONS) 
OV-16:167P196P       (BOTH MUTATIONS 167R>P,196R>P)   
OV-16:167P196R       (SINGLE MUTATION  167R>P) 
OV-16:167R196P       (SINGLE MUTATION  196R>P) 
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Samples were then tested at 1:80 dilution in 1X PBST/5% BSA (Phosphate 
buffered saline, 0.05% Tween20/ Bovine Serum Albumin) and 1ul of the humanized 
monoclonal antibody was diluted in 499ul of 1X PBST/5% FBS (Phosphate buffered 
saline, 0.05% Tween20/ Fetal Bovine Serum) which was then serially diluted using 1X 
PBST/5% FBS. All samples were tested in duplicate with each of the experimental Ov-
16 antigens under the following conditions; plates were coated with 100ul at a 
concentration of 2ug/ml of each experimental antigen; Ov-16:167R196R, Ov-
16:167P196P, Ov-16:167P196R, and Ov-16:167R196P as shown in figure 2 and 
incubated at 4o C overnight. After incubation, the plates were washed four times with 1X 
PBST and dried post fourth wash. All plates were then blocked with 1X PBST/5%BSA 
and incubated for one hour at 4o C. During this incubation step samples were diluted 
1:80 and monoclonal antibody standards were diluted. After blocking step, the plates 
were emptied and dried without washing and sample standards and controls were 
added to wells and incubated at room temperature for two hours. After incubation, the 
plates were washed four times with 1X PBST, but dried after both the first and last 
washes. An anti-human (Mouse) IgG4 antibody conjugated to biotin was then added to 
all plates at a dilution of 1:1000 in 1X PBST and incubated at room temperature for one 
hour. 1XPBST washes were repeated four times and plates were dried. Streptavidin-AP 
(Streptavidin, Alkaline Phosphatase), a conjugate used to detect biotin in signal 
amplification in combination with chromogenic or fluorogenic substrates, is added to the 
plates in a 1:2000 dilution in 1X PBST and incubated at room temperature for one hour. 
Washes were repeated four times, plates were dried, and PNPP (p-Nitrophenyl 
phosphate) 1mg/ml solution was added to the plate wells. Plate optical densities were 
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evaluated at 405nm using a BioTek® microplate reader to optimum signal output upon 
which the plates exposure was stopped using 3M NaOH. Results were analyzed for 
sensitivity and the test efficacy of the non-mutated Ov-16 antigen was compared 
between each of the mutated Ov-16 antigens.  
Testing GST Cross-Reactivity in Sera via Ov-16 ELISA 
 Plates were coated with GST at 2.0ug/ml in carbonate buffer, with the exception 
of four wells that were coated with Ov-16:167R196R (parental construct) at 2.0ug/ml in 
carbonate buffer for use with positive and negative controls. The plates were incubated 
overnight at 4o C and the protocols were followed the same as during testing Ov-16 
polymorphisms in sera via ELISA. The serum samples were tested in duplicate, with two 
negative controls and two positive controls per plate. Results were evaluated for signal 
at 405nm and any presence of cross reactivity. 
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CHAPTER THREE: 
 
RESULTS 
 
Analysis of Mutations Against the Monoclonal Antibody  
Upon evaluation of the Ov-16 ELISA that was performed using a set of pooled 
sera and the monoclonal antibody standards, it confirmed that the antigen containing 
the polymorphisms at 167 (R-P) & 196 (R-P) was unable to detect the monoclonal 
antibody appropriately (Fig. 3), while the parental antigen detected the monoclonal 
 
 
     Figure 3: OV-16 ELISA; testing efficacy of monoclonal antibody 
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antibody signal as expected (Fig.3). Taking this information into account led to isolating 
the polymorphisms so that they could be evaluated further against the monoclonal 
antibody. 
 
Isolated Mutations for Use in OV-16 ELISA 
 After purification of the four experimental Ov-16 antigens was completed via 
GSTrap HP® and Dialysis, an SDS gel electrophoresis was performed to identify the 
presence of the Ov-16 protein. Ov-16, a 16 kDa protein, which appeared at 
approximately 42 kDa when tagged to GST which has a value of 26 kDa (Fig. 4). 
 
 
                             Figure 4: SDS Analysis of purified OV-16 proteins 
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The SDS gel confirmed the presence of the desired Ov-16 protein in each of the four 
experimental antigens that were required to move forward with testing each of them 
against the monoclonal antibody and the 704 positive sera. 
 
Monoclonal Reactivity to Four Recombinant Antigens 
 The Ov-16 antigen parental construct (Ov-16:167R196R) and Ov-16 antigen 
containing a single mutation at 196 R>P (Ov-16:167R196P) displayed an OD @ 405nm 
which gave results indicating equal and strong binding to the humanized monoclonal 
antibody via Ov-16 ELISA (Fig. 5 a & b). In contrast, the Ov-16 antigen containing both 
mutations (Ov-16:167P196P) and Ov-16 antigen containing a single mutation at 167 
R>P (Ov-16:167P196R) were not capable of binding the monoclonal antibody (Fig. 5 c 
& d). 
 
 
                          Fig. 5 a                                                                                         Fig. 5 b 
           Figure 5: Monoclonal reactivity to the four recombinant OV-16 antigens (a-d) 
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                          Fig. 5 c                                                                                         Fig. 5 d 
Figure 5: Monoclonal reactivity to the four recombinant OV-16 antigens (a-d)(Cont.) 
 
These data suggest that the mutation occurring at amino-acid 167R>P (arginine to 
proline) in the Ov-16 antigen disrupted the epitope recognized by the monoclonal 
antibody. 
 
Serum Reactivity to Four Recombinant Antigens via Ov-16 ELISA 
 The positive control monoclonal antibody and patient serum samples (n=704) 
were tested via Ov-16 ELISA against the four recombinant antigens where patient sera 
were drawn from a serum bank collected in the 1980s in Liberia and Ghana; all 
individuals in this serum bank had positive skin snips, indicative of infection with O. 
volvulus. Results of the Ov-16 ELISA showed similar reactivity of the four experimental 
antigens with regards to patient sera, wherein the antigens which contained some form 
of mutation (Ov-16:167P196P, Ov-16:167P196R, & Ov-16:167R196P) were compared 
to the parental construct Ov-16 antigen (Ov-16:167R196R) (Fig. 6 a-c).  
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     Figure 6: Comparison of serum reactivity to four recombinant antigens (a-c) 
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Figure 6: Comparison of serum reactivity to four recombinant antigens (a-c) (Cont.) 
 
OV-16 ELISA Sensitivity of Polymorphisms 
 Upon evaluating whether a mutation had greater or lesser sensitivity than the 
parental construct Ov-16 antigen, it appeared that only a slight increase in sensitivity 
could be achieved when combining the antigen containing both mutations with parental 
construct Ov-16 antigen. Combining these Ov-16 antigens together increased sensitivity 
from 60.0% in Ov-16:167R196R (parental construct) to 63.5% by combining Ov-
16:167R196R (parental construct) with Ov-16:167P196P (containing both mutations) 
(Fig. 7). Upon initial investigation, it was pondered that the combined efforts of these 
Ov-16 antigens could possibly increase the sensitivity of the ELISA, which could then be 
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initiated into current protocols to optimize testing in the field. After careful evaluation 
however, it appears that the combined antigen sensitivity does not imply statistical 
significance in this case. Statistical significance was evaluated using Chi-squared test. 
In this case, Ov-16:167R196R (parental construct) and the combined Ov-16:167R196R 
(parental construct) with Ov-16:167P196P (containing both mutations), both had a 
sample size n= 704 with percentages at 60.0% and 63.5% respectively. Based on Chi-
squared test the P value was 0.18 indicating that no statistical significance exists for 
increased sensitivity when the Ov-16 antigens are combined. 
 
 
Figure 7: OV-16 ELISA; sensitivity comparisons of antigenic polymorphisms 
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Specificity was not established during this research as all 704 serum samples 
that were tested via Ov-16 ELISA were from individuals with known positive skin snips 
indicative of infection with O. volvulus.  
OV-16 ELISA GST Cross-Reactivity 
 All the serum samples tested negative for the presence of GST via Ov-16 ELISA 
upon evaluation of signal at 405nm. It was therefore determined that no cross reactivity 
with GST exists in any of the 704 serum samples that were tested indicating that all Ov-
16 positive values represent true positives for the Ov-16 portion of the fusion protein. 
Only O. volvulus was analyzed in this research, therefore it is unknown if there may be 
cross-reactivity with other filarial parasites and/or other Onchocerca spp. that could be 
present in the region where these sera were collected.   
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CHAPTER FOUR: 
 
DISCUSSION 
 
 Control programs rely on OV–16 ELISA as a diagnostic tool to evaluate the 
progress towards elimination of onchocerciasis, which is currently ongoing primarily 
through mass distribution of ivermectin, supplemented in some places with black fly 
habitat targeted control efforts (Cupp, et al., 2012). To maintain quality control and 
improve upon the Ov-16 ELISA format it is essential to evaluate the tests used for 
verifying elimination, including use of the recently developed humanized monoclonal 
antibody positive control. The importance of developing monoclonal antibodies for 
positive controls in OV-16 ELISA cannot be stressed enough. As onchocerciasis 
elimination efforts continue, it becomes increasingly important to have a set of standard 
reagents that can be utilized as positive controls. Availability of monoclonal antibody 
standards have an advantage in that; with the limited availability of pooled positive sera 
monoclonal antibodies have the potential to be effectively mass produced such that any 
need could be met. Monoclonal antibody applications could also universalize assay 
performance across the globe, making results in different regions relatable for data 
comparisons. Furthermore, these synthetic humanized antibodies could help protect 
individuals performing these tests from the risk of other infectious diseases which may 
also be present in the population where pooled sera might be selected, as it avoids the 
need of finding positive controls within a given foci which also may become harder to 
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acquire as elimination efforts continue. This helps validate why a humanized 
monoclonal antibody is a desired choice over pooled sera for positive controls. 
Furthermore, the more we learn about genetics we may find that research is no longer 
able to use a sample set of pooled sera from one region of the world to test another 
region with the same accuracy. 
 In this research, antigenic polymorphisms did express concern and possible 
limitations that exist when using a humanized monoclonal antibody for positive controls. 
Ov-16 antigens Ov-16:167P196P and Ov-16:167P196R were not appropriately 
recognized by the humanized monoclonal antibody due to unsuccessful epitope binding. 
The parental construct Ov-16 antigen (Ov-16:167R196R) and the one containing the 
single mutation at 196R>P (Ov-16:167R196P) demonstrated equivalent binding affinity 
with the monoclonal antibody. This suggests that the polymorphism occurring at 
167R>P disrupted the epitope that the monoclonal antibody recognized. There may be 
further concern as to whether or not the monoclonal antibody is able to identify the 
immunodominant epitope of interest given the possibility of other Ov-16 antigenic 
polymorphisms that may exist in the designing of Ov-16 coating antigens in the ELISA 
platform. Another proposal that may be of value would be to combine the parental 
construct Ov-16 antigen (Ov-16:167R196R) with the one which contained both 
mutations (Ov-16:167P196P), whereby creating multiple binding sites when using the 
humanized monoclonal antibody standards. 
When evaluating the polymorphisms that were detected via the Unnasch 
laboratory, there was only a slight discrepancy between the sensitivity of the four 
experimental Ov-16 antigens when evaluating the 704 sera from Liberia and Ghana. 
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However, it would be interesting to see if these mutated Ov-16 antigens would have a 
different effect when tested in other foci in varied regions where onchocerciasis is 
endemic. Another quandary to consider is the possibility that these types of 
polymorphisms may be occurring with regards to other O. volvulus parasites in different 
regions of the world which may also require evaluation of differing antigenic 
polymorphisms than those detected through this research. Furthermore, it may be 
necessary to delve into future effects of antigenic polymorphisms with regards to OV-16 
when designing synthetic monoclonal antibody controls, as well as when testing sera in 
varying foci in O. volvulus endemic regions, as variations could potentially be occurring 
in different foci similar to those noted in this research which may cause difficulty in 
creating universalized standards for Ov-16 ELISA formats. 
 To provide consistent evaluation of the ODs for each of the Ov-16 antigens, cut-
off values were standardized on a plate to plate basis at a range of 0.01 – 0.12 based 
on OD readings of the monoclonal antibody that was plated with Ov-16:167R196R 
(parental construct) and a set of sera tested against the four experimental antigens on a 
single plate. In this research, all the sera tested were from O. volvulus infected 
individuals and therefore the cut-offs were set conservatively, standard Ov-16 ELISA 
protocol typically sets cut-off values based on standards at 1:1280 with a mean OD at 
approximately 0.13 and a range between 0.06 – 0.19, evaluation at a standard cut-off of 
0.2 did not appear to change the sensitivity of the results in this investigation. Reactivity 
of the four experimental antigens with regards to patient sera also displayed a few 
outliers that may have indicated other selective epitope binding was at work. A few of 
these outliers had elevated optical densities well beyond the Ov-16:167R196R (parental 
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construct) and would be interesting to investigate further, as the antibody-antigen 
binding affinity occurring in these O. volvulus positive samples may assist with future 
test design applications to potentially increase sensitivity. When evaluating the overall 
sensitivity of the Ov-16 ELISA against the 704 serum samples from O. volvulus infected 
patients, the results were consistent with current Ov-16 ELISA applications that are in 
place in the field. Although the combined effort of Ov-16:167R196R (parental construct) 
and Ov-16:167P196P (containing both mutations) did not indicate statistical significance 
exists for increased sensitivity, the percentage difference could prove to be statistically 
sound given further evaluation with a larger sample size than that which was applied in 
this investigation (n= 704). The sensitivities of 60.0% in Ov-16:167R196R (parental 
construct), 62.6% in Ov-16:167P196P (containing both mutations), and at best 63.5% 
when combined, illustrated that there is always work to be done in order to provide the 
best possible screening capabilities with regards to Ov-16 ELISA and onchocerciasis 
elimination. As the sera obtained for use in this investigation was acquired from O. 
volvulus infected individuals in foci from Liberia and Ghana only, another avenue to 
extend future studies regarding these particular Ov-16 antigenic polymorphisms would 
be through multi-facility collaborative research efforts on O. volvulus positive sera from 
other foci in various endemic regions, such as east Africa; Uganda and Sudan, or 
possibly Yemen, that have been maintained in alternative research laboratory 
collections.   
The distribution of onchocerciasis has reduced significantly since the 1980’s due 
to the ongoing efforts of MDA programs (Cupp, et al., 2012). Although only minor 
differences were noted in the positive test results between the four experimental Ov-16 
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antigens, research of antigenic polymorphisms regarding Ov-16 ELISA may be 
essential to address the implications that can occur with current elimination efforts if 
such mutations allow false negative test results within regions of the world thought to be 
at or near elimination status. Monoclonal antibody controls should be researched further 
to account for potential antigenic polymorphisms that are occurring in the various foci 
affected by onchocerciasis which may limit the ability for these controls to work 
appropriately in Ov-16 ELISA formats when such polymorphisms are present in the 
coating antigen.  
To date there are still many challenges to face in the journey to onchocerciasis 
elimination, including the continued exploration for proficient diagnostic tools, even 
without the event of Ov-16 antigenic polymorphisms. There is also a growing need to 
explore drug alternatives; to treat high risk cases that have co-endemicity infections like 
Loa loa, to prepare for the event of possible ivermectin resistance, and to take a deeper 
look into macrofilaricides to rid the endemic population of the adult parasites which have 
the ability to perpetuate the cycle. Continued habitat targeting control methods, possibly 
aided through the use of GIS, and pooled black fly testing to detect the presence of the 
parasite within the fly should also be investigated to ensure effective elimination 
strategies are underway. Prior onchocerciasis research has paved the road in 
establishing the techniques and treatments that are currently used to control the 
disease, the path has certainly revealed continued research is necessary to build upon 
these accomplishments with more field appropriate test applications that have the 
desired specificity and sensitivity to detect recent infections in order to determine if 
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transmission is occurring, if reemergence in previously interrupted foci exists, or if 
disease interruption or elimination status has been achieved within a given foci. 
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